Infinity Laboratories to set up API unit in Behra

Infinity Laboratories Ltd to set up a active pharmaceuticals ingredient units in Behra village in Derabassi in Mohali district of Punjab. The project cost is estimated at Rs. 95 million and will produce Hydroxy phenyl glycine Dane Salt (478 tpa), Cefuroxime acid (66 tpa) and will produce sodium sulphate as by product (235 tpa).

Infinity Laboratories Private Limited H.No. 1080, Sector-12-A, Panchkula, Haryana E-mail: [email protected]

CKS Pharma Labs to set up bulk drug unit in Jaggayapet

CKS Pharma Labs Pvt Ltd to set up a bulk drug unit in Jaggayapet in Krishna district of Andhra Pradesh with an investment of Rs. 42 million. The project involves setting up of a bulk drug unit to produce Pantoprazole Sodium, Carvedilol, Lansoprazole,Prasugrel Hydrochloride, LevoCetrizine Dihydrochloride, Lamotrigine, Lamivudine, Fluconazole etc., and will have a total capacity of 15.20 mtpm.

CKS Pharma Labs H. No. 6-980, Shop No.1, Opposite to NSP Canal Office Hyderabad Road, Jagayyapet - 521175 District Krishna, Andhra Pradesh. E-mail: [email protected]

Astral Pharma receives USFDA approval for Vadodara plant

Astral Pharma which manufactures sterile antibiotic powder injectables at Makrarpura in Vadodara in Gujarat has received USFDA approval, which facilitates the company to market its product in USA. The company has already received approvals from HPFBI-Canada, TGA-Australia, MCC-South Africa and ANVISA-Brazil. It has entered into strategic business tie up with Sagent Pharmaceutical Inc with whom more than 15 Abbreviated New Drug Application (ANDAs) have been filled for US market.  At Makarpura, the company has two manufacturing facilities- one for Semi Synthetic Penicillin group and other for cephlasporin group.

Dr.Reddy Laboratories to focus on domestic sales

Dr.Reddy Laboratories which has been ranked 13th in terms of domestic sales is bringing its focus to improve its ranking. The company had been amongst the top ten few years back and lost it due to lack of focus. It plans to launch new therapeutic products in popular segments like cardiovascular, dermatology and diabetes and plans to strengthen its northern and eastern markets. The current Indian domestic market is estimated at Rs. 550,000 million and Dr.Reddys have a 2.7 % market share.